I don’t know. My own conclusion is if we failed it wouldn’t take two to three weeks of conversation with all these agencies to say “yep, we failed !”.. I’m betting on the details of the report especially around the deaths in the Leronlimab group. Parcing out the trends. Did any specific patient profiles do extremely well with Leronlimab, and conversely, was there a higher death rate in another type or types of patient profiles that tells them perhaps what the directives should be to the medical community when they use LL for s/c patients. For that type of analysis you will need a lot of data crunching ...